New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
13:25 EDTILMN, ILMN, ILMN, LMNX, LMNX, LMNX, CPHD, CPHD, CPHD, GNMK, GNMK, GNMK, NSTG, NSTG, NSTG, MYGN, MYGN, MYGN, FLDM, FLDM, FLDM, PACB, PACB, PACB, TMO, TMO, TMO, QGEN, QGEN, QGENLeerink's life science tools analyst holds an analyst/industry conference call
Life Science Tools Analyst Leonard discusses the use of nextgen sequencing in a clinical context, early applications and uptake, the merits, demerits of various nextgen sequencing instruments and where new offerings fit on an Analyst/Industry conference call. Relevant companies ILMN, TMO, PACB, FLDM, MYGN, NSTG, GNMK, CPHD, LMNX and QGEN may be discussed on the Analyst/Industry conference call to be held on April 3 at 2 pm.
News For ILMN;TMO;PACB;FLDM;MYGN;NSTG;GNMK;CPHD;LMNX;QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 28, 2015
16:11 EDTQGENQIAGEN reports Q4 adjusted EPS 25c, consensus 30c
Subscribe for More Information
15:38 EDTTMONotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Celgene (CELG), consensus 99c... ConocoPhillips (COP), consensus 59c... Abbott Laboratories (ABT), consensus 67c... Occidental Petroleum (OXY), consensus 68c... Colgate-Palmolive (CL), consensus 74c... Ford (F), consensus 23c... Dow Chemical (DOW), consensus 69c... Alibaba (BABA), consensus 75c... Thermo Fisher (TMO), consensus $1.94; Time Warner Cable (TWC), consensus $2.09... Phillips 66 (PSX), consensus $1.34... Alexion Pharmaceuticals (ALXN), consensus $1.29... Baxter International (BAX), consensus $1.31... Cardinal Health (CAH), consensus $1.10... Raytheon (RTN), consensus $1.08... Northrop Grumman (NOC), consensus $2.25... Viacom (VIAB), consensus $1.28... Valero Energy (VLO), consensus $1.32... Sherwin-Williams (SHW), consensus $1.38... Hershey (HSY), consensus $1.06... Mead Johnson (MJN), consensus 88c... Zimmer (ZMH), consensus $1.71... Xcel Energy (XEL), consensus 34c... Royal Caribbean (RCL), consensus 42c... Coach (COH), consensus 66c... Kate Spade (KATE), consensus 24c... Harley-Davidson (HOG), consensus 34c... Stanley Black & Decker (SWK), consensus $1.52... L-3 Communications (LLL), consensus $2.27... JetBlue (JBLU), consensus 24c.
15:37 EDTQGENNotable companies reporting after market close
Subscribe for More Information
09:22 EDTILMNIllumina price target raised to $230 from $200 at Wedbush
Subscribe for More Information
08:40 EDTILMNIllumina price target raised to $221 from $192 at Janney Capital
Subscribe for More Information
08:27 EDTILMNIllumina price target raised to $234 from $220 at BofA/Merrill
BofA/Merrill raised Buy rated Illumina's price target to $234 citing strong Q4 organic sales momentum.
08:13 EDTQGENQIAGEN management to meet with Evercore ISI
Subscribe for More Information
07:59 EDTILMNIllumina price target raised to $225 from $195 at Leerink
Subscribe for More Information
January 27, 2015
16:09 EDTILMNIllumina sees FY15 non-GAAP EPS $3.12-$3.18, consensus $3.20
For FY15 the Company is projecting approximately 20% revenue growth, assuming current currency exchange rates, and non-GAAP EPS of $3.12-$3.18. These projections assume full year non-GAAP gross margin of approximately 73%, and a pro forma tax rate of approximately 28%.
16:08 EDTILMNIllumina reports Q4 non-GAAP EPS 87c, consensus 78c
Reports Q4 revenue $512M, consensus $507.65M.
16:06 EDTQGENQIAGEN launches monitor to track immune function in organ transplant patients
QIAGEN N.V. announced the commercial launch of QuantiFERON Monitor, a diagnostic for monitoring immune function. QIAGEN is launching QuantiFERON Monitor in Europe as a CE-marked in-vitro diagnostic. Primary applications include monitoring of immune function in solid organ transplant recipients. In North America and other markets, QFM is available for research use as an accurate marker of immune function in studies of immunosuppressive conditions, immune modulating therapies and recovery following transplantation.
15:04 EDTQGENQIAGEN management to meet with Leerink
Meeting to be held in New York on February 3 hosted by Leerink.
January 26, 2015
07:17 EDTMYGNSociety of Thoracic Surgeons to hold annual meeting
51st Annual Meeting of STS is being held in San Diego, California on January 24-28.
January 23, 2015
15:46 EDTPACB, MYGN, ILMN, LMNX, FLDMPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
January 21, 2015
10:24 EDTILMNIllumina pulls back following State of the Union address
Shares of Illumina (ILMN) rose yesterday after a biotech industry website reported that President Obama might unveil a major new genomics project during his State of the Union address last night. That speculation was backed as a possibility by an analyst at Wells Fargo ahead of last night's address. In the speech, President Obama unveiled what he called his Precision Medicine Initiative, which relies on genomics to "deliver(s) the right treatment at the right time." Obama spent far more time, however, discussing economic growth and foreign relations than healthcare. Illumina shares are down 3% to $190.64 in early trading today.
January 20, 2015
13:45 EDTILMNIllumina rises as genomics project seen being announced in State of the Union
Subscribe for More Information
11:24 EDTILMNIllumina could see headline boost from U.S. genomics project, says Wells Fargo
After biotech industry publication BioCentury said Friday that the president may announce a new genomics project to sequence up to one million human genomes as part of his State of the Union speech tonight, Wells Fargo said that it believes such an announcement could be a headline catalyst for Illumina since it would mean the U.S. needs additional sequencing capacity. However, such a project would be long-term in nature, Wells Fargo cautioned, adding that such a plan would more likely support existing Illumina growth assumptions than push those forecasts up. Shares of Illumina are up 6% to $194.85 in morning trading ahead of tonight's speech by the president.
07:53 EDTFLDMFluidigm upgraded to Outperform at Cowen
Subscribe for More Information
07:07 EDTMYGNMyriad RBM joins Institut Pasteur in TB collaboration
Myriad RBM, a wholly owned subsidiary of Myriad Genetics, announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis, or TB, epidemic. This research project is funded by the Bill & Melinda Gates Foundation through a grant to the Institut Pasteur. The proof-of-concept study will evaluate patients with latent and active TB infections who are affiliated with the South African Tuberculosis Vaccine Initiative clinical study sites. The goals of this study are to field-test Myriad RBM's TruCulture system as a point-of-care blood collection and immune response monitoring method and to stratify patients with active and latent tuberculosis.
06:36 EDTFLDMFluidigm upgraded to Outperform from Market Perform at Cowen
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use